Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
Last zynerba pharmaceuticals earnings: 3/10 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations: ir.zynerba.com
- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - FAB0C Month 12: ADAMS Percent Improvement from Baseline with ZYN002 FAB-C Month 12: ABC-CFXS Percent Improvement from Baseline with ZYN002 - Presentation Today at the 57th Annual Meeting of the American College of Neuropsychopharmacology - DEVON, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders,
[Read more]
| Impact snapshot | Event time: | ZYNE | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ZYNE alerts
ZYNE alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYNE alerts
High impacting Zynerba Pharmaceuticals news events
Weekly update
A roundup of the hottest topics
ZYNE
News
- Zynerba Pharmaceuticals (ZYNE) Investor Presentation - Slideshow [Seeking Alpha]Seeking Alpha
- Zynerba Pharmaceuticals, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ZYNE/price-target/">NASDAQ: ZYNE</a>) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational HighlightsGlobeNewswire
- Zynerba Pharmaceuticals, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ZYNE/price-target/">NASDAQ: ZYNE</a>) had its price target raised by analysts at Cantor Fitzgerald from $6.00 to $8.00. They now have an "overweight" rating MarketBeat
- Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X SyndromeGlobeNewswire
- More
ZYNE
SEC Filings
- 5/12/21 - Form 424B5
- 5/12/21 - Form S-8
- 5/12/21 - Form 10-Q
- ZYNE's page on the SEC website
- More